Founded in 2015, Geneoscopy is revolutionizing gastrointestinal health by giving patients and providers better insights into disease. The company’s proprietary technology extracts and quantifies eukaryotic RNA biomarkers (seRNA) from stool samples. These biomarkers form the basis for innovative assays that help detect and monitor gastrointestinal diseases, including colorectal cancer, in a noninvasive way. By combining cutting-edge science with patient-focused solutions, Geneoscopy is improving early detection and treatment outcomes.
Geneoscopy has achieved several key milestones in its mission to improve colorectal cancer screening:
From its earliest days, Geneoscopy benefited from BioGenerator’s comprehensive support. The company began in the BioGenerator Labs, where access to state-of-the-art infrastructure allowed it to test and refine its technology. BioGenerator provided non-dilutive funding to validate the company’s initial hypothesis and invested in Geneoscopy’s seed round, offering board guidance that helped navigate early growth challenges.
Beyond financial support, BioGenerator played a strategic role in professional due diligence, helping Geneoscopy secure its $105M Series B in 2021 and attract key investors. This combination of lab space, funding, mentoring, and strategic support laid the foundation for Geneoscopy’s continued success.
“BioGenerator played a critical and diverse role in Geneoscopy's development and maturation. From the financial, mentoring, and physical infrastructure support provided to launch Geneoscopy through the BioGenerator Labs, to leading an independent diligence process to catalyze our Series B, which resulted in a key strategic investor joining the round, BioGenerator has been instrumental to our company's success.”
Andrew Barnell, Co-Founder & CEO, Geneoscopy
